AbCellera Biologics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ABCL research report →
Range $9 – $30
Price Chart
About the company
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs.
- CEO
- Carl Hansen
- IPO
- 2020
- Employees
- 562
- HQ
- Vancouver, BC, CA
Get TickerSpark's AI analysis on ABCL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.16B
- P/E
- -22.98
- PEG
- -1.57
- P/S
- 53.09
- P/B
- 3.30
- EV/EBITDA
- -25.77
- Div Yield
- 0.00%
- Gross Margin
- 75.57%
- Op Margin
- -297.97%
- Net Margin
- -218.54%
- ROE
- -15.35%
- ROIC
- -12.23%
Latest fiscal year · YoY change
- Revenue
- $75.13M+160.6%
- Gross Profit
- $46.31M+60.6%
- Op Income
- $-217,103,000
- Net Income
- $-146,412,000+10.1%
- EPS
- $-0.49+10.9%
- OCF Growth
- -20.9%
- FCF Growth
- +6.9%
- 52W High
- $15.02
- 52W Low
- $2.75
- 50D MA
- $12.32
- 200D MA
- $7.39
- Beta
- 1.19
- RSI (14)
- 38
- Avg Volume
- 4.35M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
AbCellera said Q3 was a breakthrough quarter, led by strong Phase II data for ABCL635 in hot flashes, while also adding new internal programs and ending the quarter with a very strong cash position.· November 9, 2026
- ABCL635 posted strong Phase II results with rapid, placebo-adjusted improvements in hot flashes and favorable tolerability, and management said it now plans late-stage development next year.
- The company said ABCL635’s 4-week data showed an 83% reduction in daily hot flash events versus 33% for placebo, and a 58% reduction in severity versus 12% for placebo.
- AbCellera announced ABCL992, a next-generation, half-life extended version of ABCL635, and said ABCL688, ABCL386, ABCL385 and ABCL646 are also moving through or into early development.
- The company will not pursue ABCL575 in atopic dermatitis after poor external readouts in the OX40/OX40L class, despite Phase I data showing favorable PK and tolerability.
- Liquidity was reinforced by a significantly oversubscribed $200 million capital raise, and management said it has enough capital to fund at least the next 3 years of pipeline investments.
Q3 revenue was over $10 million, versus approximately $9 million in the same quarter of 2025. R&D expense was approximately $44 million, while SG&A was approximately $14 million versus $25 million last year. The company reported a net loss of roughly $41 million, or a loss of $0.13 per share, compared with a loss of about $57 million a year earlier. Cash and equivalents were over $790 million at quarter-end, with over $100 million in available committed government funding; management said total available liquidity is over $890 million. ABCL635 Phase II results included a 4-week reduction in moderate/severe hot flash events of 8.8 per day versus 3.5 for placebo, and severity fell 1.4 points versus 0.3 for placebo. The company said it expects to disclose additional 12-week and open-label extension data in early 2027 and expects to initiate late-stage development for menopause-related VMS in 2027; it also expects to start clinical trials in breast and prostate cancer hot flashes in 2027.
Carl Hansen framed the quarter as a transition point for AbCellera, saying the company has moved from a platform story to a clinical biotech with two programs successfully through early development. He emphasized that ABCL635 is the key asset, describing the data as breakthrough and saying it creates the path to a potentially category-defining women’s health product. He also highlighted pipeline expansion with ABCL992, ABCL385 and ABCL646, and said the company is focused on building repeatable drug-creation capabilities rather than being a one-program story.
Andrew Booth said AbCellera ended Q3 with over $790 million in cash and equivalents, over $100 million in committed government funding, and more than $890 million in available liquidity when combined. He noted the $200 million oversubscribed equity raise, which contributed to $214 million of financing cash inflows along with government funding and stock option exercises. He also said year-to-date operating activities generated $19 million in cash, capital expenditures were about $8 million, and the company now has about $600 million invested in short-term marketable securities. He concluded that capital needs are manageable and that liquidity should be sufficient to fund at least the next 3 years of pipeline investments.
Analysts focused heavily on ABCL635’s commercialization path, including clinician reaction, the planned 12-week and open-label extension data, and whether management might include an active comparator in late-stage studies. Management said the reception from clinicians was extremely positive, that the 12-week timing shifted to early 2027 mainly as a preferred release window rather than due to an operational issue, and that it is still in regulatory and KOL discussions on final trial design and dose selection. Questions also centered on ABCL992’s market role and whether the company would license out internal assets; management said the longer half-life could improve convenience and COGS and that out-licensing remains possible depending on the program. For ABCL575, management said they are not taking it beyond Phase I at this time because of external class-wide setbacks.
The call presented a clear lead asset in ABCL635 with strong efficacy, rapid onset, and no clear gastrointestinal or liver toxicity signal, which management believes could support a best-in-class nonhormonal option for hot flashes. Investors also got a cleaner story on balance sheet strength, with more than $890 million in available liquidity and enough capital to fund multiple years of pipeline work. The company also showed pipeline breadth by adding ABCL992, ABCL385 and ABCL646 while advancing ABCL688 and ABCL386.
ABCL635 still has key de-risking steps ahead, including 12-week data, open-label extension data, regulatory alignment on dose selection, and final pivotal trial design. Management also said they are still working through patient populations, endpoints and study design details for prostate cancer and some late-stage plans, which adds execution risk. Outside of ABCL635, ABCL575 will not move forward beyond Phase I and the broader pipeline remains early, with several assets still in IND-enabling work and no disclosed clinical data yet.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 64.0%
- Shares Outstanding
- 326.62M
- Float Shares
- 209.04M
of shares held by institutions
168 13F filers
Buy/sell ratio 2.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Baker Bros. Advisors LP | 33.01M | ▲ 2.74M |
| Capital World Investors | 13.58M | ▼ 9.23K |
| Two Sigma Investments, LP | 10.44M | ▼ 124.63K |
| Marshall Wace, Llp | 8.96M | ▲ 7.06M |
| Bank Of America Corp | 6.14M | ▲ 3.14M |
| Blackrock, Inc. | 5.66M | ▲ 1.86M |
| Two Sigma Advisers, LP | 4.88M | ▲ 78.10K |
| Ubs Am, A Distinct Business Unit Of Ubs Asset Management Americas LLC | 4.32M | ▼ 3.26M |
| Arrowmark Colorado Holdings LLC | 4.11M | 0 |
| Driehaus Capital Management LLC | 2.86M | ▼ 1.16M |
| Tudor Investment Corp Et Al | 2.06M | ▼ 210.30K |
| Arrowstreet Capital, Limited Partnership | 2.01M | ▲ 973.74K |
Held by 69 ETFs
Biggest fund positions in ABCL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 13, 26 | Booth Andrew | other | 50,000 |
| Nov 13, 26 | Booth Andrew | other | 50,000 |
| Nov 13, 26 | Booth Andrew | other | 50,000 |
| Nov 13, 26 | Thermopylae Holdings Ltd. | other | 125,000 |
| Nov 13, 26 | Booth Andrew | buy | 8,600 |
| Nov 12, 26 | Thermopylae Holdings Ltd. | buy | 60,565 |
| Aug 24, 26 | Hayden Michael R | buy | 53,613 |
| Aug 18, 26 | Montalbano John S. | buy | 10,000 |
| Aug 14, 26 | Booth Andrew | buy | 37,200 |
| Aug 12, 26 | Hayden Michael R | buy | 46,387 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ABCL coverage
Recent articles, reports, and earnings notes.

Iambic Therapeutics IPO Preview: AI Drug Discovery Meets Clinical Risk
Iambic Therapeutics Inc. (NASDAQ: IAM) is expected to list on 2026-10-15, and the IPO has priced at $16.00 per share after offering 9,375,000 shares. The company did not disclose a price range in the materials provided. The bull case is a fast-growing collaboration platform with clinical-stage assets; the bear case is that it still has to prove AI can translate into durable drug wins.

AI Biotech Stocks That Show Real Progress: 7 September 2026 Picks
This countdown spans AI-native drug discovery, computational chemistry, genomics, diagnostics, antibody platforms and data-rich biotech businesses.
Want a deeper read on ABCL?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
AbCellera Biologics Inc. (ABCL) Presents at UBS Global Biopharma Conference 2026 Transcript
seekingalpha.com · Nov 17
AbCellera Biologics Targets 2027 Late-Stage Trial for Hot Flash Treatment
marketbeat.com · Nov 16
AbCellera Biologics Inc. (ABCL) Presents at Stifel 2026 Healthcare Conference 2026 Transcript
seekingalpha.com · Nov 13
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year?
zacks.com · Nov 12
AbCellera Biologics Eyes Phase 3 for Hot-Flash Drug After Promising Midstage Results
marketbeat.com · Nov 12
AbCellera Biologics Inc. (ABCL) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 9
What AbCellera Biologics (ABCL) Said on Its Q3 Earnings Call
marketbeat.com · Nov 9
AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Tops Revenue Estimates
zacks.com · Nov 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.